Quest Diagnostics Incorporated Q2 2026 Earnings Recap

The 8.6% stock gain reflects investor approval of Quest Diagnostics’ broad-based revenue growth and strong adjusted EPS increase, supported by robust demand across clinical, hospital, and consumer segments and raised full-year guidance.

Key Takeaways

• Revenues grew over 10% year-over-year, driven by physician, hospital, and consumer health demand, including collaborations with Corewell Health and Fresenius Medical Care.
• Adjusted diluted EPS increased by more than 19%, bolstered by automation and AI in lab operations improving quality and productivity.
• Double-digit revenue growth was noted in hospital partnerships, consumer wellness services (including new thyroid testing), and several advanced diagnostics areas such as cardiometabolic, autoimmune, brain health, and oncology.
• The company expanded its oncology test access with New York State approval of Haystack MRD and integration with Flatiron Health’s Onco EMR platform, enabling broader commercial reach.
• Management raised full-year guidance, signaling confidence in sustained demand driven by demographic and technological trends.